FDA Clears Neurora, a New AI Tool to Help Diagnose Autism in Children (2026)
Quick answer: On October 2, 2026, the U.S. FDA cleared Neurora, an AI-based software tool from Argus Cognitive that helps clinicians diagnose autism in children aged 18 months to 12 years. It analyzes video and audio from a standard behavioral assessment. It does not diagnose autism on its own; a clinician still makes the call.
If you are waiting on an autism evaluation for your child, you know how long that wait can feel. New tools that make evaluations faster and more confident matter to every family on that list. Here is what Neurora is, how it works, and what it means for you.
What is Neurora?
Neurora is a Class II medical device made of software only. The FDA classifies it as a “pediatric autism spectrum disorder diagnosis aid” (510(k) number K260064). It was developed by Argus Cognitive, Inc., a company founded in 2016 in Hanover, New Hampshire. Its development was supported by a Small Business Innovation Research grant from the National Institutes of Health (NIH).
How does Neurora work?
- A clinician runs the behavioral assessment they already use with your child.
- The session is recorded on video and audio.
- The clinician uploads the recording to the Neurora portal.
- The software measures more than 100 vocal, facial and gaze biometrics, such as speech patterns, facial expressions and where your child looks.
- Neurora reports how closely your child’s behavior aligns with children with and without an autism diagnosis.
- The clinician combines that report with everything else they observed and makes the diagnosis.
No special glasses, headsets or hardware are needed, and the clinic does not have to change its assessment protocol.
Does Neurora replace the doctor?
No. Neurora is intended for use alongside the diagnostic process and is not a stand-alone diagnostic tool. Its co-founder and clinical lead, Dr. Latha Valluripalli Soorya, who directs the AARTS autism center at Rush University Medical Center, put it simply: the clinician still makes the call. Think of it as a second set of very precise eyes, not a replacement for an experienced evaluator.
Why does this matter for families?
According to the CDC, about 1 in 31 U.S. children is autistic. Yet the median age of diagnosis is still close to 4, and only about half of autistic children are evaluated by age 3. Early diagnosis opens the door to early intervention, which is when support tends to make the biggest difference.
Tools like Neurora aim to give clinicians objective, measurable data. That can add confidence to a diagnosis, especially when the observation was recorded by someone else on the team. One honest caveat: neither the company nor the FDA listing shows that Neurora shortens waiting lists yet. That is something to watch.
How is Neurora different from other FDA-cleared autism tools?
| Tool | What it analyzes | Ages |
|---|---|---|
| Neurora (Argus Cognitive), cleared 2026 | Video + audio of a standard clinical assessment; 100+ vocal, facial and gaze measures | 18 months – 12 years |
| Canvas Dx (Cognoa) | Parent questionnaire, provider input and home videos | 18 months – 6 years |
| EarliPoint Evaluation | Eye-tracking while the child watches short social videos | 16 months – under 8 years (latest clearance) |
Neurora’s wide age range stands out. Many children, especially girls and kids with strong verbal skills, are not diagnosed until school age.
Can parents use Neurora at home?
Not directly. Neurora is sold to clinics and health systems, and only a healthcare professional can use it. If you are on a waiting list, you can ask your developmental pediatrician, psychologist or evaluation center whether they use Neurora or plan to. Clinics can learn more at neurorahealth.com.
What should parents do now?
- Don’t wait for a new tool. If you see early signs, ask your pediatrician for a screening such as the M-CHAT-R/F.
- Ask your evaluation center which tools it uses and how long the wait is.
- Start early intervention services while you wait; in the U.S. you can request a free Early Intervention evaluation for children under 3 without a diagnosis.
- Bring short home videos of your child to the appointment. Clinicians find them useful with or without AI tools.
The bottom line
Neurora is a promising step toward faster, more objective autism evaluations for children from toddlerhood through age 12. It supports clinicians rather than replacing them. For families, the best move is still the same: screen early, ask questions, and start support as soon as you can.
Frequently asked questions
What is Neurora?
Neurora is FDA-cleared software from Argus Cognitive that helps clinicians diagnose autism in children aged 18 months to 12 years. It analyzes video and audio from a standard behavioral assessment.
When did the FDA clear Neurora?
The FDA cleared Neurora on October 2, 2026, under 510(k) number K260064. Argus Cognitive announced it on October 8, 2026.
Can AI diagnose autism?
Not on its own. FDA-cleared tools like Neurora give clinicians objective data, but a qualified healthcare professional makes the diagnosis.
What does Neurora measure?
It measures more than 100 vocal, facial and gaze biometrics, then reports how closely a child’s behavior aligns with children with and without an autism diagnosis.
Can parents buy or use Neurora at home?
No. Neurora is used by clinics and health systems. Parents can ask their child’s evaluator whether they use it.
How early can autism be diagnosed?
Autism can often be reliably diagnosed by age 2. Yet the U.S. median age of diagnosis is close to 4, which is the gap tools like Neurora aim to help close.
Will Neurora shorten autism waiting lists?
It may help clinicians work more efficiently, but there is no published evidence yet that it shortens wait times.
This article is for information only and is not medical advice. Talk to a qualified healthcare provider about your child’s development.
Discover more from Living with Autism
Subscribe to get the latest posts sent to your email.
